Cytokinetics, Incorporated (CYTK) Balance Sheet
CYTK balance sheet, 2025
December 31, 2025 · U.S. dollars$1.42B assets = $2.08B liabilities + −$659.6M equity
Liabilities exceed assets: shareholders’ equity is negative (−$659.6M).
Both columns are drawn to the same scale: what CYTK owns equals what it owes plus shareholders’ equity. Hover a block for its value.
CYTK financial health
Current ratio4.53
Comfortable · current assets cover current liabilities 4.53×
Equity / assets−46.3%
Thin equity · of assets funded by shareholders
Cash / debt68.7%
Partial cover · cash & short-term investments vs total debt
Goodwill & intangibles0.0%
Mostly tangible · of total assets
Descriptive bands, not a rating. Fiscal 2025.
CYTK balance sheet trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $170.1M2016 | $1.42B2025 | +26.6%/yr | |
| Total liabilities | $75.8M2016 | $2.08B2025 | +44.5%/yr | |
| Shareholders’ equity | $94.4M2016 | −$659.6M2025 | — | |
| Cash & short-term investments | $156.2M2016 | $882.2M2025 | +21.2%/yr | |
| Total debt | $29.9M2016 | $1.28B2025 | +51.9%/yr | |
| Net cash (debt) | $126.4M2016 | −$402.0M2025 | −$528.4M | |
| Working capital | $125.4M2016 | $714.5M2025 | +$589.1M | |
| Book value per share | $2.222016 | −$5.492025 | — | |
| Current ratio | 4.772016 | 4.532025 | −0.24 | |
| Debt / equity | 0.322016 | 1.112021 | +0.79 | |
| Shares outstanding | 42.6M2016 | 120.1M2025 | +12.2%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
CYTK assets
Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current
CYTK liabilities and equity
Current liabilitiesLong-term debtOther long-term liabilitiesEquity
CYTK debt vs cash
Total debtCash & ST investmentsNet cash (debt)
Debt includes short- and long-term borrowings and, where reported, lease obligations.
CYTK balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $882.2M | $1.08B | $614.8M | $782.6M | $471.6M | $464.1M | $225.1M | $198.7M | $268.9M | $156.2M |
| Cash & equivalents | $122.5M | $94.9M | $113.0M | $65.6M | $112.7M | $83.0M | $36.4M | $42.3M | $125.2M | $66.9M |
| Short-term investments | $759.7M | $981.2M | $501.8M | $717.0M | $359.0M | $381.1M | $188.7M | $156.5M | $143.7M | $89.4M |
| Receivables | $17.8M | $16.6M | $1.3M | $147,000 | $51.8M | $4.4M | $5.2M | $6.8M | $1.1M | $24,000 |
| Inventory | $0 | $0 | −$11.9M | −$147,000 | −$51.8M | −$4.4M | $0 | −$6.8M | $1 | $0 |
| Other current assets | $17.0M | $15.3M | $23.9M | $12.6M | $64.0M | $10.2M | $3.5M | $8.9M | $4.3M | $2.4M |
| Total current assets | $917.0M | $1.11B | $628.1M | $795.2M | $535.7M | $474.2M | $233.8M | $207.7M | $274.3M | $158.6M |
| Property, plant & equipment (net) | $155.2M | $141.0M | $147.7M | $163.2M | $146.4M | $16.3M | $13.4M | $3.2M | $3.6M | $3.6M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $335.0M | $145.1M | $40.5M | $46.7M | $152.1M | $37.0M | $42.6M | $0 | $16.5M | $7.7M |
| Other non-current assets | $17.3M | $7.7M | $8.0M | $9.7M | $7.2M | $6.4M | $0 | $300,000 | $429,000 | $200,000 |
| Total assets | $1.42B | $1.40B | $824.3M | $1.01B | $841.3M | $533.8M | $289.8M | $211.2M | $294.8M | $170.1M |
| Liabilities | ||||||||||
| Accounts payable | $22.3M | $20.4M | $21.5M | $25.6M | $21.1M | $8.1M | $8.2M | $3.8M | $5.3M | $4.2M |
| Short-term debt | $60.3M | $30.5M | $28.0M | $13.8M | $14.9M | $2.8M | $4.6M | $2.6M | $5.3M | $2.5M |
| Deferred revenue | $1.6M | $52.4M | $17.9M | — | $34.4M | $19.3M | $12.1M | $15.8M | $9.6M | $8.1M |
| Total current liabilities | $202.5M | $179.7M | $102.7M | $84.6M | $71.9M | $31.2M | $26.0M | $22.2M | $32.4M | $33.3M |
| Long-term debt | $1.12B | $645.6M | $607.4M | $63.8M | $47.4M | $46.2M | $45.1M | $39.8M | $31.8M | $27.4M |
| Lease obligations | $127.1M | $131.6M | $138.3M | $139.7M | $127.1M | $3.2M | $6.8M | — | — | — |
| Other long-term liabilities | $765.7M | $711.8M | $500.6M | $974.2M | $478.2M | $343.0M | $229.7M | $123.2M | $120.7M | $15.1M |
| Total liabilities | $2.08B | $1.54B | $1.21B | $1.12B | $597.5M | $420.4M | $300.8M | $185.2M | $185.0M | $75.8M |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $123,000 | $118,000 | $102,000 | $94,000 | $84,000 | $70,000 | $59,000 | $768.8M | $54,000 | $41,000 |
| Retained earnings (deficit) | −$3.49B | −$2.70B | −$2.11B | −$1.59B | −$1.21B | −$992.3M | −$865.0M | −$743.3M | −$646.1M | −$518.3M |
| Treasury stock | — | — | — | — | — | — | — | $0 | $0 | $0 |
| Accumulated other comprehensive income | $630,000 | $2.4M | −$10,000 | −$3.6M | −$869,000 | $149,000 | $679,000 | $500,000 | $343,000 | $137,000 |
| Minority interest | — | — | — | — | — | — | — | $0 | $0 | $0 |
| Total shareholders' equity | −$659.6M | −$135.4M | −$386.3M | −$107.9M | $243.9M | $113.4M | −$10.9M | $25.9M | $109.8M | $94.4M |
| Key figures | ||||||||||
| Total debt | $1.28B | $788.7M | $755.8M | $750.3M | $269.9M | $138.9M | $136.1M | $42.4M | $37.0M | $29.9M |
| Net cash (debt) | −$402.0M | $287.3M | −$140.9M | $32.3M | $201.7M | $325.1M | $89.0M | $156.3M | $231.9M | $126.4M |
| Working capital | $714.5M | $928.3M | $525.4M | $710.6M | $463.8M | $443.0M | $207.7M | $185.5M | $241.9M | $125.4M |
| Tangible book value | −$659.6M | −$135.4M | −$386.3M | −$107.9M | $243.9M | $113.4M | −$10.9M | $25.9M | $109.8M | $94.4M |
| Book value per share | −$5.49 | −$1.21 | −$4.00 | −$1.20 | $3.17 | $1.76 | −$0.19 | $0.48 | $2.22 | $2.22 |
| Shares outstanding | 120.1M | 112.0M | 96.5M | 89.8M | 76.9M | 64.5M | 57.6M | 54.4M | 49.4M | 42.6M |
| Current ratio | 4.53 | 6.17 | 6.12 | 9.40 | 7.45 | 15.20 | 8.98 | 9.36 | 8.45 | 4.77 |
| Quick ratio | 4.45 | 6.08 | 6.00 | 9.25 | 7.28 | 15.02 | 8.85 | 9.26 | 8.32 | 4.70 |
| Debt / equity | — | — | — | — | 1.11 | 1.23 | — | 1.64 | 0.34 | 0.32 |
| Equity / assets | −46.3% | −9.7% | −46.9% | −10.6% | 29.0% | 21.2% | −3.8% | 12.3% | 37.3% | 55.5% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $1.17B | $818.5M | $882.2M | $962.5M | $858.1M | $938.2M | $1.08B | $1.01B | $1.06B | $619.0M | $615.2M | $539.2M |
| Cash & equivalents | $255.3M | $129.8M | $122.5M | $225.5M | $74.9M | $73.7M | $94.9M | $46.9M | $190.5M | $120.0M | $113.4M | $99.7M |
| Short-term investments | $910.4M | $688.7M | $759.7M | $737.1M | $783.2M | $864.5M | $981.2M | $964.8M | $866.6M | $499.0M | $501.8M | $439.5M |
| Receivables | $24.4M | $6.8M | $17.8M | $1.8M | $8.4M | $2.0M | $16.6M | $244,000 | $0 | $834,000 | $1.3M | $2.5M |
| Inventory | $380,000 | $154,000 | $0 | $0 | $0 | $0 | $0 | −$244,000 | $0 | −$834,000 | $0 | −$2.5M |
| Other current assets | $18.0M | $13.9M | $17.0M | $13.0M | $20.0M | $15.8M | $15.3M | $6.9M | $10.7M | $19.7M | $11.6M | $22.2M |
| Total current assets | $1.21B | $839.5M | $917.0M | $977.3M | $886.5M | $956.1M | $1.11B | $1.02B | $1.07B | $638.7M | $628.1M | $561.4M |
| Property, plant & equipment (net) | $151.8M | $157.0M | $155.2M | $153.6M | $146.3M | $144.6M | $141.0M | $140.6M | $142.9M | $146.2M | $147.7M | $155.5M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $538.3M | $254.7M | $335.0M | $288.8M | $178.2M | $150.7M | $145.1M | $269.2M | $305.4M | $15.4M | $40.5M | $15.5M |
| Other non-current assets | $25.9M | $22.3M | $17.3M | $16.8M | $14.6M | $12.7M | $7.7M | $7.7M | $7.7M | $7.8M | $8.0M | $8.2M |
| Total assets | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808.1M | $824.3M | $740.6M |
| Liabilities | ||||||||||||
| Accounts payable | $20.5M | $24.7M | $22.3M | $22.1M | $16.2M | $13.9M | $20.4M | $11.6M | $9.5M | $13.0M | $21.5M | $13.8M |
| Short-term debt | $48.4M | $65.8M | $60.3M | $37.9M | $34.0M | $32.5M | $30.5M | $30.4M | $30.0M | $29.8M | $28.0M | $17.2M |
| Deferred revenue | $1.7M | $1.7M | $1.6M | $1.6M | $1.3M | $52.4M | $52.4M | — | −$38.3M | −$40.1M | — | $33.0M |
| Total current liabilities | $181.4M | $199.2M | $202.5M | $142.1M | $131.1M | $159.7M | $179.7M | $109.8M | $102.8M | $88.9M | $102.7M | $77.7M |
| Long-term debt | $1.12B | $1.12B | $1.12B | $1.05B | $713.0M | $645.2M | $645.6M | $644.5M | $643.4M | $606.6M | $607.4M | $609.0M |
| Lease obligations | $123.5M | $126.2M | $127.1M | $131.3M | $130.6M | $132.9M | $131.6M | $133.6M | $135.2M | $136.8M | $138.3M | $139.5M |
| Other long-term liabilities | $796.9M | $783.1M | $765.7M | $767.3M | $750.2M | $725.6M | $711.8M | $695.7M | $669.0M | $508.8M | $500.6M | $492.7M |
| Total liabilities | $2.10B | $2.10B | $2.08B | $1.96B | $1.59B | $1.53B | $1.54B | $1.45B | $1.42B | $1.20B | $1.21B | $1.18B |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $138,000 | $124,000 | $123,000 | $122,000 | $119,000 | $119,000 | $118,000 | $118,000 | $117,000 | $105,000 | $102,000 | $94,000 |
| Retained earnings (deficit) | −$3.89B | −$3.69B | −$3.49B | −$3.30B | −$3.00B | −$2.86B | −$2.70B | −$2.55B | −$2.39B | −$2.25B | −$2.11B | −$1.98B |
| Accumulated other comprehensive income | −$3.8M | −$1.6M | $630,000 | $34,000 | −$158,000 | $1.5M | $2.4M | $5.4M | −$1.0M | −$539,000 | −$10,000 | −$874,000 |
| Total shareholders' equity | −$173.5M | −$826.6M | −$659.6M | −$521.1M | −$368.7M | −$266.4M | −$135.4M | −$13.9M | $108.5M | −$396.2M | −$386.3M | −$438.8M |
| Key figures | ||||||||||||
| Total debt | $1.27B | $1.29B | $1.28B | $1.20B | $858.1M | $791.1M | $788.7M | $789.6M | $790.2M | $754.9M | $755.8M | $748.5M |
| Net cash (debt) | −$104.9M | −$470.2M | −$402.0M | −$234.3M | $77,000 | $147.2M | $287.3M | $222.1M | $267.0M | −$136.0M | −$140.6M | −$209.2M |
| Working capital | $1.03B | $640.3M | $714.5M | $835.2M | $755.5M | $796.3M | $928.3M | $908.8M | $965.0M | $549.8M | $525.4M | $483.7M |
| Tangible book value | −$173.5M | −$826.6M | −$659.6M | −$521.1M | −$368.7M | −$266.4M | −$135.4M | −$13.9M | $108.5M | −$396.2M | −$386.3M | −$438.8M |
| Book value per share | −$1.31 | −$6.71 | −$5.39 | −$4.34 | −$3.09 | −$2.25 | −$1.15 | −$0.12 | $0.99 | −$3.89 | −$3.90 | −$4.57 |
| Shares outstanding | 132.1M | 123.3M | 122.4M | 120.0M | 119.5M | 118.5M | 118.1M | 117.7M | 109.2M | 101.9M | 99.1M | 96.1M |
| Current ratio | 6.66 | 4.21 | 4.53 | 6.88 | 6.76 | 5.99 | 6.17 | 9.28 | 10.39 | 7.19 | 6.12 | 7.22 |
| Quick ratio | 6.56 | 4.14 | 4.45 | 6.78 | 6.61 | 5.89 | 6.08 | 9.22 | 10.29 | 6.98 | 6.00 | 6.97 |
| Debt / equity | — | — | — | — | — | — | — | — | 7.28 | — | — | — |
| Equity / assets | −9.0% | −64.9% | −46.3% | −36.3% | −30.1% | −21.1% | −9.7% | −1.0% | 7.1% | −49.0% | −46.9% | −59.2% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed February 26, 2026); data from EODHD.
CYTK financial position
At the end of fiscal 2025 (December 31, 2025), Cytokinetics had total assets of $1.4 billion (up 1.6% from a year earlier), total liabilities of $2.1 billion and shareholders' equity of -$659.6 million. It held $882.2 million in cash and short-term investments against $1.3 billion of debt, net debt of $402.0 million. Its current ratio was 4.53. In the latest quarter (ended June 30, 2026) total assets were $1.9 billion and equity -$173.5 million.
Related: CYTK income statement, CYTK cash flow statement, CYTK key metrics. See the CYTK stock overview for the latest quote and news.
CYTK balance sheet FAQ
What are Cytokinetics's total assets?
Cytokinetics reported total assets of $1.4 billion at the end of fiscal 2025 (December 31, 2025), compared with $1.4 billion a year earlier.
How much debt does Cytokinetics have?
Cytokinetics had $1.3 billion of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was —.
How much cash does Cytokinetics have?
Cytokinetics held $882.2 million in cash and short-term investments at the end of fiscal 2025; with $1.3 billion of debt that is net debt of $402.0 million.
What is Cytokinetics's book value?
Cytokinetics's shareholders' equity (book value) was -$659.6 million at the end of fiscal 2025, or −$5.49 per share.
What is Cytokinetics's current ratio?
Cytokinetics had current assets of $917.0 million and current liabilities of $202.5 million, a current ratio of 4.53 (it can cover its short-term obligations).